The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases


Turk C., OKAY M. , TÜRK S. , Temirci E. S. , Javad O., AKSU S. , ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, ss.661-674, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 49 Konu: 2
  • Basım Tarihi: 2019
  • Doi Numarası: 10.3906/sag-1807-152
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Sayfa Sayıları: ss.661-674

Özet

Background/aim: Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, it has been proposed that ruxolitinib-induced JAK/STAT pathway inhibition in myelofibrosis is associated with an elevated frequency of aggressive B-cell lymphomas. However, the biological basis and significance of this pharmacobiological adverse event is unknown. The aim of this bioinformatics study is to detect any possible confounding effects of ruxolitinib on the genesis of lymphoproliferative disorders.